These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 8158848)
1. [Relationship between prognosis of multiple myeloma and response to VCAP therapy]. Umeda M; Annoh S; Takata M; Shikoshi K; Katoh M; Shirai T Rinsho Ketsueki; 1994 Mar; 35(3):272-8. PubMed ID: 8158848 [TBL] [Abstract][Full Text] [Related]
2. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. Luo SK; Li J; Hong WD; Zhao Y; Tong XZ Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805 [TBL] [Abstract][Full Text] [Related]
3. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma]. Wutke K; Anger G Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459 [TBL] [Abstract][Full Text] [Related]
4. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
5. [Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma]. Umeda M; Shirai T; Tsukahara T; Kaneko H; Yamauchi M; Arai N; Kosuge T; Kato M; Shikoshi K; Anno S Rinsho Ketsueki; 1991 Jun; 32(6):669-74. PubMed ID: 1890744 [TBL] [Abstract][Full Text] [Related]
7. [The efficacy of polychemotherapy programs in treating multiple myeloma patients]. Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636 [TBL] [Abstract][Full Text] [Related]
8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
9. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
10. [Clinical response to the treatment of multiple myeloma]. Sezaki T Rinsho Ketsueki; 1989 Aug; 30(8):1216-9. PubMed ID: 2601037 [TBL] [Abstract][Full Text] [Related]
11. [VCAP therapy of multiple myeloma]. Umeda M; Kaneko H; Katoh M; Yamaguchi R; Masaki T; Ishikawa I; Yamauchi M; Kiga Y; Hara A; Nojima Z Rinsho Ketsueki; 1987 Jul; 28(7):1147-51. PubMed ID: 3694822 [No Abstract] [Full Text] [Related]
12. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252 [TBL] [Abstract][Full Text] [Related]
13. Early response to therapy and survival in multiple myeloma. Schaar CG; Kluin-Nelemans JC; le Cessie S; Franck PF; te Marvelde MC; Wijermans PW Br J Haematol; 2004 Apr; 125(2):162-6. PubMed ID: 15059138 [TBL] [Abstract][Full Text] [Related]
14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
15. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Riccardi A; Mora O; Tinelli C; Valentini D; Brugnatelli S; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Giordano M; Delfini C; Nicoletti G; Bergonzi C; Rinaldi E; Piccinini L; Ascari E Br J Cancer; 2000 Apr; 82(7):1254-60. PubMed ID: 10755397 [TBL] [Abstract][Full Text] [Related]
16. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
17. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S; Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805 [TBL] [Abstract][Full Text] [Related]
18. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038 [TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
20. [Progress in the treatment of multiple myeloma]. Wada M; Mizoguchi H Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]